Keywords: Allergan, MAP Pharma, Levadex, Co-promotion, USA, Migraine
Allergan and MAP Pharma collaborate on Levadex for acute migraine, in deal worth potential $157 million
Article | 02 February 2011
US drugmakers Allergan (NYSE: AGN) and MAP Pharmaceuticals (Nasdaq: MAPP) have entered a collaboration within the USA for Levadex (dihydroergotamine), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
